NASDAQ:ANL Adlai Nortye (ANL) Stock Price, News & Analysis $10.18 -0.34 (-3.23%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Adlai Nortye Stock (NASDAQ:ANL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adlai Nortye alerts:Sign Up Key Stats Today's Range$9.91▼$10.6050-Day Range$9.37▼$16.6052-Week Range$0.88▼$17.25Volume51,287 shsAverage Volume358,205 shsMarket Capitalization$655.59 millionP/E RatioN/ADividend YieldN/APrice Target$29.50Consensus RatingModerate Buy Company Overview Adlai Nortye is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2004 and headquartered in Hangzhou, China, the company conducts drug research and development for potential use in China and international markets. Its investigational oncology pipeline includes AN2025, a pan-RAF inhibitor; AN0025, an EP4 antagonist; and AN4005, an adenosine A2A/A2B receptor antagonist. These candidates are being studied for their potential to treat solid tumors, including in combination with other cancer therapies. Adlai Nortye’s products are investigational and have not been established as approved treatments. The company’s work centers on advancing its drug candidates through clinical development.AI Generated. May Contain Errors. Read More Adlai Nortye Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreANL MarketRank™: 2.06306542546 of 5 starsAdlai Nortye scored higher than 41% of companies evaluated by MarketBeat, and ranked 659th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAdlai Nortye has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAdlai Nortye has a consensus price target of $29.50, representing about 180.4% upside from its current price of $10.52.Amount of Analyst CoverageAdlai Nortye has only been the subject of 3 research reports in the past 90 days.Read more about Adlai Nortye's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adlai Nortye are expected to decrease in the coming year, from ($0.21) to ($0.36) per share. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.00% of the float of Adlai Nortye has been sold short.Short Interest Ratio / Days to CoverAdlai Nortye has a short interest ratio ("days to cover") of 27.38, which indicates bearish sentiment.Change versus previous monthShort interest in Adlai Nortye has recently increased by 13.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdlai Nortye does not currently pay a dividend.Dividend GrowthAdlai Nortye does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.75 News SentimentAdlai Nortye has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adlai Nortye this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ANL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adlai Nortye insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $411,060.00 in company stock.Percentage Held by Institutions35.21% of the stock of Adlai Nortye is held by institutions.Read more about Adlai Nortye's insider trading history. Receive ANL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adlai Nortye and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANL Stock News HeadlinesANL - Adlai Nortye Group Ltd.November 9, 2026 | seekingalpha.comAdlai Nortye (NASDAQ:ANL) Stock Rating Lowered by Wall Street ZenNovember 2, 2026 | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 13 at 1:00 AM | Weiss Ratings (Ad)Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR SymposiumOctober 27, 2026 | globenewswire.comAdlai Nortye Strikes Global Clinical Collaboration with Lilly and Merck for AN4035 Combination TrialOctober 15, 2026 | tipranks.comAdlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and CetuximabOctober 15, 2026 | globenewswire.comAdlai Nortye Group: Only For The Risk-Tolerant After A Massive RallyOctober 8, 2026 | seekingalpha.comMajor Insider Move Shakes Up Adlai Nortye Sponsored ADROctober 1, 2026 | tipranks.comSee More Headlines ANL Stock Analysis - Frequently Asked Questions How have ANL shares performed this year? Adlai Nortye's stock was trading at $1.42 at the start of the year. Since then, ANL shares have increased by 640.8% and is now trading at $10.52. When did Adlai Nortye IPO? Adlai Nortye (ANL) raised $58 million in an initial public offering on Friday, September 29th 2023. The company issued 2,500,000 shares at $23.00 per share. Who are Adlai Nortye's major shareholders? Adlai Nortye's top institutional investors include State Street Corp (0.06%), ACT Capital Partners L.P. (0.04%) and China Universal Asset Management Co. Ltd.. Insiders that own company stock include Xiaofeng Ye, Ping Ji and Yang Lu. View institutional ownership trends. How do I buy shares of Adlai Nortye? Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/13/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ANL's financial health is in the Green zone, according to TradeSmith. ANL has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANL Previous SymbolNASDAQ:ANL CIK1944552 Webwww.adlainortye.com Phone848-230-7430FaxN/AEmployees109Year Founded2004Price Target and Rating Average Price Target for Adlai Nortye$29.50 High Price Target$49.00 Low Price Target$20.00 Potential Upside/Downside+188.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio9.55 Quick RatioN/A Sales & Book Value Annual Sales$5 million Price / Sales131.63 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-48.67Miscellaneous Outstanding Shares64,400,000Free FloatN/AMarket Cap$658.17 million OptionableNot Optionable Beta1.36 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ANL) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
